OLMA vs. ELVN, SNDX, COLL, SYRE, BCYC, NTLA, RCKT, ZYME, ADPT, and GYRE
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Enliven Therapeutics (ELVN), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), Spyre Therapeutics (SYRE), Bicycle Therapeutics (BCYC), Intellia Therapeutics (NTLA), Rocket Pharmaceuticals (RCKT), Zymeworks (ZYME), Adaptive Biotechnologies (ADPT), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.
Olema Pharmaceuticals vs.
Olema Pharmaceuticals (NASDAQ:OLMA) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 19.4% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 29.2% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Enliven Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Olema Pharmaceuticals presently has a consensus price target of $27.00, suggesting a potential upside of 380.00%. Enliven Therapeutics has a consensus price target of $38.25, suggesting a potential upside of 73.16%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Enliven Therapeutics.
In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 4 mentions for Olema Pharmaceuticals and 2 mentions for Enliven Therapeutics. Olema Pharmaceuticals' average media sentiment score of 1.34 beat Enliven Therapeutics' score of 0.24 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.
Olema Pharmaceuticals received 21 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 67.39% of users gave Olema Pharmaceuticals an outperform vote.
Enliven Therapeutics' return on equity of -29.46% beat Olema Pharmaceuticals' return on equity.
Olema Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
Summary
Enliven Therapeutics beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:OLMA) was last updated on 1/21/2025 by MarketBeat.com Staff
